Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filings
MORE TOOLS
WatchlistGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View GYRE insider activity ↗

GYREGYRE THERAPEUTICS, INC.

THE LATEST REPORTED YEAR

The company reported a profit.

$9.88M net income for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$116.59MYear ended December 31, 2025
Profit or loss$9.88MYear ended December 31, 2025
Cash from the business$1.01MYear ended December 31, 2025
Total assets$199.26MAs of June 30, 2026
Total liabilities$34.34MAs of June 30, 2026
Cash & equivalents$43.29MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$1.02M
2017-12
$6K
2018-12
$20.95M
2020-12
$7.34M
2021-12
$102.29M
2022-12
$113.45M
2023-12
$105.76M
2024-12
$116.59M
2025-12

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
January 1, 2025 – December 31, 2025$116,588,000March 13, 202610-K ↗
January 1, 2024 – December 31, 2024$105,757,000March 13, 202610-K ↗
January 1, 2023 – December 31, 2023$113,450,000March 17, 202510-K ↗
January 1, 2022 – December 31, 2022$102,290,000March 27, 202410-K ↗
January 1, 2021 – December 31, 2021$7,338,000March 31, 202210-K ↗
January 1, 2020 – December 31, 2020$20,948,000March 31, 202210-K ↗
January 1, 2018 – December 31, 2018$6,000February 20, 202010-K ↗
January 1, 2017 – December 31, 2017$1,018,000March 8, 201910-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 12, 2026

Response SHA-256: 76d6d577c67b9fd5657091e03be7ffe01a1cac0d3d9b5ad24843327a50d791e0

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.